|
MS (n = 16) |
NMOSD (n = 16) |
ONDs
(n = 15) |
Men:women |
4:12 |
2:14 |
9:6 |
Age, y |
36.5 (18–51) |
61.0 (27–86) |
61.4 (42–75) |
Disease duration, y |
4.9 (0–20) |
5.8 (0–40) |
- |
EDSS |
6.0 (1.0–9.0) |
6.3 (1.5–9.0) |
- |
Positive AQP4 antibody |
0/16 (0%) |
16/16 (100%) |
- |
Positive OCB |
10/14 (71%) |
2/14 (14%) |
- |
CSF cells, /mm3 |
3.5 (0–43) |
4.7 (1–64) |
0.7 (0–3) |
CSF TP, mg/dL |
32 (19–50) |
51 (17–160) |
37 (18–71) |
Qalb, ×10−2
|
4.9 (2.7–11.7) |
6.0 (2.8–37.0) |
4.0
(2.7–6.2) |
Immunomodulating therapy |
4/16 (25%) |
5/16 (31%) |
0/15
(0%) |